Диссертация (1141239), страница 27
Текст из файла (страница 27)
Am J Gastroenterol2004;99:1887–94.50.Fass R, Hell RW, Garewal HS, etal. Correlation of oesophageal acidexposure with Barrett's oesophagus length. Gut 2001;48: 310-313.51.Fisher RS, Bromer MQ, Thomas RM, Cohen S, Krevsky B, Horwitz B,Glazier KD, Das K, Das KM.
Predictors of recurrent specialized intestinalmetaplasia after complete laser ablation. // Am J Gastroenterol. 2003 Sep;98(9):1945-51.52.Fitzgerald RC, di Pietro M, Ragunath K, Ang Y, Kang JY, Watson P,Trudgill N, Patel P, Kaye PV, Sanders S, O‘Donovan M, Bird-Lieberman E,Bhandari P, Jankowski JA, Attwood S, Parsons SL, Loft D, Lagergren J, MoayyediP, Lyratzopoulos G, de Caestecker J. British Society of Gastroenterology161guidelines on the diagnosis and management of Barrett‘s oesophagus.
Gut 2014;63: 7-42.53.Galipeau PC, Li X, Blount PL, Maley CC, Sanchez CA, Odze RD, et al.NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression toesophageal adenocarcinoma. PLoS Med 2007;4:e67.54.GeboesK.Barrett'sesophagus:themetaplasia-dysplasia-carcinomasequence: morphological aspects.
// Acta Gastroenterol Belg. 2000 JanMar;63(l):13-7.55.Gurski R.R., Peters J.H., Hagen J.A., DeMeester S.R., Bremner C.G.,Chandrasoma P.T., DeMeester T.R. Barrett‗s esophagus can and does regress afterantireflux surgery: a study of prevalence and predictive features. J Am Coll Surg.2003.56.Hameeteman M., Tytgat G.N.J., Houthoff H.J., van der Tweel J.R. Barrett'sesophagus, development of dysplasia and adenocarcinoma // Gastroenterology.
1989. - Vol. 96. - P. 1249-1256.57.Hanahan D. and R. A.Weinberg, ―Hallmarks of cancer: the next generation,‖Cell, vol. 144, no. 5, pp. 646–674, 2011.58.Hoffmann AC, Vallbohmer D, Prenzel K, Metzger R, Heitmann M, Neiss S,et al. Methylated DAPK and APC promoter DNA detection in peripheral blood issignificantly associated with apparent residual tumor and outcome. J Cancer ResClin Oncol 2009;135:1231–7.59.Hofstetter WL, Peters JH, DeMeester TR, et al.
Long-term outcome ofantirefluxsurgeryinpatientswithBarrett'soesophagus.AnnSurg2001;234:532e8. discussion 538e539.60.Hvid-Jensen F, Pedersen L, Drewes AM, et al. Incidence of adenocarcinomaamong patients with Barrett's oesophagus. N Engl J Med 2011;365:1375e83.61.Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics.2009; CA Cancer J.
Clin. 2009; 59: 225–49.62.Jobe BA, Hunter JG, Chang EY, et al. Office-based unsedated small-caliberendoscopy is equivalent to conventional sedated endoscopy in screening and162surveillance for Barrett's esopha¬gus: a randomized and blinded comparison. Am JGastroenterol 2006;101:2693-2703.63.Johnston MH, Eastone J A, Horwhat JD, Cartledge J, Mathews JS, FoggyJR. Cryoablation of Barrett's esophagus: a pilot study. // Gastrointest Endosc. 2005Dec;62(6):842-8.64.Kahaleh M, Van Laethem JL, Nagy N, Cremer M, Deviere J.
Long-termfollow-up and factors predictive of recurrence in Barrett's esophagus treated byargonplasmacoagulationandacidsuppression.//Endoscopy.2002Dec;34(12):950-5.65.Kara MA, Ennahachi M, Fockens P, etal. Detection and classification of themucosal and vascular patterns (mucosal morphology) in Barrett's esophagus byusing narrow band imaging.
Gastrointest Endosc 2006;64:155-166.66.Kawakami K, Brabender J, Lord RV, Groshen S, Greenwald BD, KrasnaMJ, et al. Hypermethylated APC DNA in plasma and prognosis of patients withesophageal adenocarcinoma. J Natl Cancer Inst 2000;92:1805–11.67.Kaz A.M., Wong C.J., Luo Y., Virgin J.B., et al. DNA methylation profilingin Barrett‘s esophagus and esophageal adenocarcinoma reveals unique methylationsignatures and molecular subclasses. Epigenetics. 2011; (6:12): 1403-1412.68.Kuramochi H, Vallbohmer D, Uchida K, et al. Quantitative, tissue-specificanalysis of cyclooxygenase gene expression in the pathogenesis of Barrett'sadenocarcinoma.
J Gastrointest Surg 2004;8:1007e16. discussion 1016e1007.69.Lagergren J. Adenocarcinoma of oesophagus: what exactly is the size of theproblem and who is at risk? Gut. 2005;54(suppl 1):i1–i5; Spechler SJ. Dysplasia inBarrett‘s esophagus: limitations of current management strategies. Am JGastroenterol. 2005;100:927–935.70.Levine D.S., Haggitt R.C., Irvine S., Reid B. Natural history of highgradedisplasia in Barrett's esophagus // Gastroenterology.
- 1996. - Vol. 110. - P. A550.71.Li X, Galipeau PC, Sanchez CA, Blount PL, Maley CC, Arnaudo J, et al.Single nucleotide polymorphism-based genome-wide chromosome copy change,163loss of eterozygosity, and aneuploidy in Barrett's esophagus neoplasticprogression. Cancer Prev Res 2008;1:413–23.72.Litle VR, Buenaventura PO, Luketich JD. Minimally invasive resection foresophageal cancer. Surg Clin North Am. 2002;82:711–728.73.Lofdahl HE, Lane A, Lu Y, et al. Increased population prevalence of refluxand obesity in the United Kingdom compared with Sweden: a potential explanationfor the difference in incidence of esophageal adenocarcinoma. Eur J GastroenterolHepatol. 2011;23:128–32.74.Loffeld R.J., Werdmuller B.F., Kuster J.G.
et al. Colonization with cagA-positive Helicobacter pylori strains inversely associated with reflux esophagitis andBarrett's esophagus // Digestion. - 2000. - Vol. 62. -N 2-3. - P. 95-99.75.Lomo LC, Blount PL, Sanchez CA, Li X, Galipeau PC, Cowan DS, Ayub K,Rabinovitch PS, Reid BJ, Odze RD. Crypt dysplasia with surface maturation: aclinical, pathologic, and molecular study of a Barrett's esophagus cohort. // Am JSurg Pathol. 2006 Apr;30(4):423-35.76.Lord R.V. Ann Surg.
1999 March; 229(3): 428–439. PMCID: PMC1191710Norman Barrett, "doyen of esophageal surgery".77.Low DE, Levine DS, Dail DH, Kozarek RA. Histological and anatomicchanges in Barrett's oesophagus after antireflux surgery. Am J Gastroenterol1999;94:80e5.78.Makuuchi H.
Barrett's esophageal cancer // Gan. To Kagaku Ryoho. - 2002.-Vol. 29.-N2.-P. 161-168.79.Martinez de Haro LF, Ortiz A, Parrilla P, et al. Long-term follow-up ofmalignancy biomarkers in patients with Barrett's oesophagus undergoing medicalor surgical treatment. Ann Surg 2012;255:916e21.80.May A., Gossner L., Pech O. et al. Local endoscopic therapy for intra-epithelial high-grade neoplasia and early adenocarcinoma in Barrett's oesophagus:acute-phase and intermediate results of a new treatment approach // Eur. J.Gastroenterol. Hepatol.
- 2002. - Vol. 14.-N10.-P. 1085-1091.16481.McDonald ML, Trastek VF, Allen MS, et al. Barretts's oesophagus: does anantireflux procedure reduce the need for endoscopic surveillance? J ThoracCardiovasc Surg 1996;111:1135e8. discussion 1139e1140.82.Menges M., Michaeli B., Pueschel W. et al. The influence of the suppressionof gastroesophageal reflux on the gene expression pattern in Barrett's oesophagus//Int. J. Oncol. - 2002. - Vol. 20.
-N 6. - P. 1323-1329.83.Milind R, Attwood SE. Natural history of Barrett‘s esophagus.World JGastroenterol 2012; 18: 3483-3491.84.Montgomery E, Goldblum JR, Greenson JK, Haber MM, Lamps LW,Lauwers GY, Lazenby AJ, Lewin DN, Robert ME, Washington K, Zahurak ML,Hart J. Dysplasia as a predictive marker for invasive carcinoma in Barrettesophagus: a follow-up study based on 138 cases from a diagnostic variabilitystudy.
//Hum Pathol. 2001 Apr;32(4):379-88.85.Morson B.C., Belcher J.R. Adenocarcinoma of the esophagus and ectopicgastric mucosa.Br J Cancer. 1952.86.Murray L, Sedo A, Scott M, McManus D, Sloan JM, Hardie LJ, et al. TP53and progression from Barrett's metaplasia to oesophageal adenocarcinoma in a UKpopulation cohort. Gut 2006;55:1390–7.87.Naef A.P., Savary M., Ozzello L. Columnar-lined lower esophagus: anacquired lesion with maliganant predisposition: report on 140 cases of Barrett‘sesophagus with 12 adenocarcinomas. J.
ThoracCardiovasc Surg. 1975.88.Nigro J.J., Bremner R.M., Fuller C.B. et al. Perforating Barrett's ulcer re-sulting in a life-threatening esophagobronchial fistula // Ann. Thorac. Surg. - 2002.- Vol. 73.-N1.-P. 302-304.89.Nigro J.J., Hagen J.A., DeMeester T.R. et al. Prevalence and location ofnodal metastases in distal esophageal adenocarcinoma confined to the wall:implications for therapy // J. Thorac.
Cardiovasc. Surg. - 1999. - Vol. 117. - P. 1625.16590.Oberg S, Johansson J, Wenner J, et al. Endoscopic surveillance of columnar-lined oesophagus: frequency of intestinal metaplasia detection and impact ofantireflux surgery. Ann Surg 2001;234:619e26.91.Oberg S, Wenner J, Johansson J, et al. Barrett oesophagus: risk factors forprogression to dysplasia and adenocarcinoma. Ann Surg 2005;242:49e54.92.Oberg S., Ritter M.P., Crookes P.F. et al. Gastroesophageal reflux diseaseand mucosal injury with emphasis on short-segment Barrett's esophagus andduodenogastroesophageal reflux.
J. Gastrointest. Surg. - 1998. - Vol. 2. - P. 547554.93.Oelschlager BK, Barreca M, Chang L, et al. Clinical and pathologicresponse of Barrett's oesophagus to laparoscopic antireflux surgery. Ann Surg2003;238:458e64. discussion 464e456.94.Oh DS, DeMeester SR, Vallbohmer D, et al.
Reduction of interleukin 8 geneexpression in reflux esophagitis and Barrett's oesophagus with antireflux surgery.Arch Surg 2007;142:554e9. discussion 559e560.95.O'Riordan JM, Byrne PJ, Ravi N, et al. Long-term clinical and pathologicresponse of Barrett's esophagus after antireflux surgery. Am J Surg 2004;188:2733.96.Orringer M. Transchiatal esophagectomy for benign disease // J. Thorac.Cardiovasc. Surg. - 1985.
- Vol. 90. -N 5. - P. 649-655.97.Parrilla P, Martinez de Haro LF, Ortiz A, et al. Long-term results of arandomized prospective study comparing medical and surgical treatment ofBarrett's oesophagus [see comment] Ann Surg 2003;237:291e8.98.Paull A, Trier JS, Dalton MD, Camp RC, Loeb P, Goyal RK. The histologicspectrum of Barrett‘s esophagus. NEnglJMed. 1976.99.Paulson TG, Maley CC, Li X, etal. Chromosomal instability and copynumber alterations in Barrett's esophagus and esophageal adenocarcinoma.